The conundrum of platelet P2Y12 inhibition in ST-segment elevation myocardial infarction

Circulation Journal

Volumn 80, Issue 12, 2016, Pages 2429-2431

  Rollini, Fabiana ^a   Franchi, Francesco ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; P2RY12 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; EDITORIAL; HEMODYNAMICS; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMIC PARAMETERS; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; METABOLISM; PATHOLOGY; THROMBOCYTE;

BLOOD PLATELETS; HUMANS; RECEPTORS, PURINERGIC P2Y12; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 84997497906     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-1063     Document Type: Editorial

References (14)

1. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12: 30-47.
2. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
3. Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: Insights from the National Cardiovascular Data Registry. J Am Heart Assoc 2014; 3: e000849, doi:10.1161/JAHA.114.000849.
4. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
5. Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015; 8: 1457-1467.
6. Ichikawa S, Tsukahara K, Minamimoto Y, Kimura Y, Matsuzawa Y, Maejima N, et al. Pharmacodynamic assessment of platelet reactivity after a loading dose of prasugrel or clopidogrel in patients with ST-segment elevation myocardial infarction. Circ J 2016; 80: 2520-2527.
7. Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: The CRUSH study. J Am Coll Cardiol 2016; 67: 1994-2004.
8. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684-1692.
9. Zeymer U, Mochmann HC, Mark B, Arntz HR, Thiele H, Diller F, et al. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: The ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv 2015; 8: 147-154.
10. Alexopoulos D, Gkizas V, Patsilinakos S, Xanthopoulou I, Angelidis C, Anthopoulos P, et al. Double versus standard loading dose of ticagrelor: Onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol 2013; 62: 940-941.
11. Alexopoulos D, Makris G, Xanthopoulou I, Patsilinakos S, Deftereos S, Gkizas V, et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Pharmacodynamic study. Circ Cardiovasc Interv 2014; 7: 233-239.
12. Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, et al. Ticagrelor crushed tablets administration in STEMI patients: The MOJITO study. J Am Coll Cardiol 2015; 65: 511-512.
13. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, et al. Prasugrel versus tirofiban bolus with or without short postbolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: The FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5: 268-277.
14. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-1313.